Friday, July 10, 2026

Drug profile · INN

ibuprofen lysine

ibuprofen lysine (NEOPROFEN) is a cyclooxygenase inhibitor. Route of administration: intravenous. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — ibuprofen lysine
US status
approved
Class
Route
INTRAVENOUS
Patents
0
Programs
0
Data quality
0.84

Quick answer

ibuprofen lysine (NEOPROFEN) is a cyclooxygenase inhibitor. Route of administration: intravenous. Current US regulatory status: approved.

Key facts

INN ibuprofen lysine
Brand NEOPROFEN
Mechanism Cyclooxygenase inhibitor
Target Cyclooxygenase
Route INTRAVENOUS
Formulation INJECTABLE

Mechanism of action

Cyclooxygenase inhibitor

Primary target: Cyclooxygenase

Approval history

Authority Status Date
FDA approved

Related & competitor drugs

  1. aspirin Cyclooxygenase inhibitor
  2. bromfenac sodium Cyclooxygenase inhibitor
  3. diclofenac potassium Cyclooxygenase inhibitor
  4. diclofenac sodium Cyclooxygenase inhibitor
  5. diflunisal Nervous system (N02)
  6. fenoprofen calcium Cyclooxygenase inhibitor

Frequently asked questions

What is ibuprofen lysine?

ibuprofen lysine (NEOPROFEN) is a cyclooxygenase inhibitor. Route of administration: intravenous. Current US regulatory status: approved.

What is the brand name for ibuprofen lysine?

NEOPROFEN is a marketed brand name for ibuprofen lysine. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of ibuprofen lysine?

ibuprofen lysine has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.